Zimmer Biomet stock (US98956P1021): Q1 2026 revenue beat and August earnings watch

Zimmer Biomet reported stronger-than-expected Q1 2026 revenue and EPS on April 28, while investors now look ahead to the next earnings update expected in August.

Zimmer Biomet is back on investors’ radar after it reported first-quarter 2026 results on April 28, with revenue and earnings both coming in above Wall Street expectations. For U.S. investors, the company remains a closely watched medical technology name tied to elective procedures, hospital spending, and orthopedic demand.

On April 28, 2026, Zimmer Biomet said first-quarter revenue was $2.09 billion and adjusted EPS was $2.09, according to Zimmer Biomet IR as of 04/28/2026. MarketBeat’s earnings page lists the company’s next estimated earnings date as August 6, 2026, which puts the stock into a key reporting window for traders watching hospital and orthopedic spending trends.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zimmer Biomet
• Sector/industry: Medical technology / orthopedic devices
• Headquarters/country: United States
• Core markets: Orthopedics, surgical implants, trauma, joint replacement
• Key revenue drivers: Knee, hip, and surgical product sales
• Home exchange/listing venue: NYSE (ZBH)
• Trading currency: USD

Zimmer Biomet: core business model

Zimmer Biomet develops and sells orthopedic and surgical products used in hospitals, ambulatory surgery centers, and other care settings. Its portfolio includes knee and hip systems, trauma products, biologics, and surgical tools, which makes the company sensitive to procedure volumes and purchasing cycles.

The company’s website highlights a broad set of product lines, including surgical solutions and specialty platforms, according to Zimmer Biomet product pages as of 05/22/2026. That product mix matters for U.S. investors because orthopedic device demand often tracks elective care recovery, reimbursement dynamics, and operating-room utilization.

Zimmer Biomet also has exposure beyond the United States, but its shares trade on the NYSE and the company is regularly benchmarked against other U.S.-listed medtech names. That makes quarterly execution, margin trends, and management commentary especially relevant for retail investors following healthcare equipment stocks.

Main revenue and product drivers for Zimmer Biomet

Orthopedic implants remain the company’s core revenue engine, with knee and hip systems historically among the most important categories. Management and investors typically watch those lines alongside trauma, extremities, and surgical products, since changes in procedure volumes can affect both top-line growth and operating leverage.

The company’s publicly available product pages also show newer and adjacent offerings, including digital and surgical-assist tools such as OrthoGrid, which points to a broader strategy around workflow and surgical support. For a medtech company, these products can help deepen relationships with surgeons and hospital systems even when core implant markets are competitive.

Zimmer Biomet said first-quarter 2026 revenue reached $2.09 billion, while adjusted EPS also came in at $2.09, according to the company’s April 28 release. The next scheduled earnings date is estimated for August 6, 2026, based on MarketBeat’s calendar, which gives investors a near-term catalyst to watch as the year moves into the second half.

Why Zimmer Biomet matters for US investors

Zimmer Biomet is relevant to U.S. investors because it sits in a large and recurring healthcare spending category: orthopedic procedures. A rebound in joint replacement volumes, hospital capital budgets, or surgeon adoption can lift sentiment, while slower elective care trends can pressure expectations.

The stock also serves as a window into broader medtech conditions in the United States, where reimbursement, staffing, and patient volume can affect device makers differently than drug companies. For retail investors, that makes Zimmer Biomet a company whose quarterly results often matter more than day-to-day macro headlines.

Conclusion

Zimmer Biomet enters the next phase of 2026 with a Q1 report that showed revenue and EPS ahead of expectations and a follow-up earnings date now on the calendar for August. The company’s orthopedic focus keeps it tied to procedure trends, hospital demand, and competitive execution in the U.S. medtech market. For investors, the setup is less about one-quarter noise and more about whether recent operating momentum can continue into the next report.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.